Introduction of curative direct-acting antiviral (DAA) agents has transformed the treatment for HCV both pre- and post-liver transplantation (LT).12 Post-LT cure rates with DAAs are now >95%. However, LT recipients… Click to show full abstract
Introduction of curative direct-acting antiviral (DAA) agents has transformed the treatment for HCV both pre- and post-liver transplantation (LT).12 Post-LT cure rates with DAAs are now >95%. However, LT recipients are burdened with renal and metabolic comorbidities, and little is known about the benefits of HCV cure on extrahepatic complications of HCV, particularly diabetes mellitus (DM) and renal impairment after LT. This article is protected by copyright. All rights reserved.
               
Click one of the above tabs to view related content.